# US 2023/0265389 A1 · Method of transfecting macrophages

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265389 A1
- Document ID: US20230265389A1
- Status: Published application
- Kind: A1
- Application number: 17/927,793
- Filed: 2021-05-27
- Published: 2023-08-24
- Earliest claimed: 2020-05-27
- Assignees: The University Court of the University of Edinburgh
- Applicants: The University Court of The University of Edinburgh
- Inventors: Stuart Forbes; Lara Campana; Benjamin Dwyer; Philip Starkey Lewis; John Campbell; Alasdair Fraser
- Web page: https://patentgrep.com/patent/US20230265389A1

## CPC

- C12N 13/00: Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
- A61K 40/17: Monocytes; Macrophages
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/40: characterised by antigens that are targeted or presented by cells of the immune system
- C12N 5/0645: {Macrophages, e.g. Kuepfer cells in the liver; Monocytes}
- C12N 15/85: for animal cells
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C12M 35/02: {Electrical or electromagnetic means, e.g. for electroporation or for cell fusion}
- C12N 2510/00: Genetically modified cells
- C12N 2800/107: for mammalian
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The development of the method of the invention enables the efficient and reproducible production of genetically modified GMP-grade human macrophages. The inventors have described the effects of the method described on cell viability and efficiency of introduction of genetic material into macrophages. Unlike previous methods of introducing genetic material into macrophages, excellent conditions are demonstrated which produce efficient transgene expression, without compromising cell viability. Critically, the method of the invention does not use virus to introduce genetic material, is efficacious on mature cells, are functional with in vitro assay and in vivo transfer in a liver disease model and complies with practices compatible with manufacture and delivery of these cells to patients.

## Claims

### Claim 1

A method of transfecting a human macrophage with genetic material, the method comprising the steps of:
(a) contacting a human macrophage with genetic material;
(b) electroporating the macrophage with a first pulse phase, wherein the first pulse phase comprises a burst of unipolar pulses or a square pulse, wherein each pulse is between 750-1000V, and wherein the first pulse phase lasts for a total period of between 20-500 µs; and
(c) electroporating the macrophage with a second pulse phase, wherein the second pulse phase comprises a burst of pulses or a square pulse, wherein each pulse is between 50-225 V, and wherein the second pulse phase lasts for a total period of 2000-50000 µs.

### Claim 2 (depends on 1)

A method according to claim 1, wherein each pulse in the first pulse phase is selected from:
i) between 800-1000 V;
ii) between 850-1000 V;
iii) between 900-1000 V;
iv) between 950-1000 V; or
v) about 950 V.

### Claim 3

A method according to any preceding claim, wherein the first pulse phase is for a total period of time selected from:
i) between 40-180 µs;
ii) between 80-120 µs; or
iii) about 120 µs.

### Claim 4

A method according to any preceding claim, wherein the first pulse phase comprises a burst of unipolar pulses and the second pulse phase comprises a burst of unipolar pulses.

### Claim 5

A method according to any preceding claim, wherein each pulse in the second pulse phase is selected from:
i) between 80-200 V;
ii) between 85-175 V;
iii) between 90-150 V;
iv) between 95-125 V; or
v) about 100-125 V.

### Claim 6

A method according to any preceding claim, wherein the second pulse phase is for a total period of time selected from:
i) between 11000-30000 µs;
ii) between 12000-30000 µs;
iii) between 11000-25000 µs;
iv) between 12000-25000 µs;
v) between 11000-23000 µs;
vi) between 12000-23000 µs; or
vii) about 23000 µs.

### Claim 7

A method according to any preceding claim, wherein the burst of unipolar pulses are positive or negative pulses.

### Claim 8

A method according to any preceding claim, wherein the genetic material comprises a nucleic acid, preferably DNA or RNA.

### Claim 9

A method according to any preceding claim, wherein the genetic material comprises one or more nucleic acids encoding one or more genes of interest and/or regulatory elements.

### Claim 10

A method according to any preceding claim, wherein the genetic material comprises one or more nucleic acids encoding a homologous or heterologous gene of interest, preferably a heterologous gene of interest.

### Claim 11

A method according to any preceding claim, wherein the genetic material is comprised on a vector, preferably a plasmid.

### Claim 12

A method according to any preceding claim where the human macrophages are human monocyte derived macrophages.

### Claim 13

A method according to any preceding claim, wherein the human macrophage is contacted with genetic material in solution, preferably the solution is conductive, preferably the solution is an electroporation buffer.

### Claim 14 (depends on 13)

A method according to claim 13, wherein the human macrophage is present in the solution at a cell density selected from:
i) between 1×105 to 1×109cells/mL;
ii) between 5×105 to 8×108 cells/mL:
iii) between 1×106 to 6×108 cells/mL;
iv) between 5×106 to 5×108 cells/mL;
v) between 5×107 to 1.5×108/mL;
vi) between 1×107/mL to 1×109/mL or
v) 5×107 cells/mL.

### Claim 15 (depends on 13, 14)

A method according to any of claims 13 or 14, wherein the genetic material is present in the solution at a concentration selected from:
i) between 1 to 10 µg per 5×106 macrophage cells;
ii) between 3 to 9 µg per 5×106 macrophage cells;
iii) between 4 to 8 µg per 5×106 macrophage cells; or
iv) between 5 to 7.5 µg per 5×106 macrophage cells.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A transfected human macrophage produced by the method of any of claims 1-15.

### Claim 17

A transfected human macrophage comprising a heterologous nucleic acid, wherein the macrophage has a repressed STING pathway and optionally wherein the macrophage has reduced expression of IFN-β.

### Claim 18 (depends on 17)

A transfected human macrophage according to claim 17, wherein the macrophage is polarized.

### Claim 19 (depends on 16, 17, 18)

A population of transfected human macrophages according to claims 16 to 18.

### Claim 20

A population of transfected human macrophages comprising a viability selected from of at least:
(i) 60%;
ii) 70%;
iii) 80%;
iv) 85%;
v) 90%; or
vi) 95%,
and wherein said population of macrophages optionally comprises a heterologous nucleic acid.

### Claim 21 (depends on 20)

A population of transfected macrophages according to claim 20, wherein the macrophages have a repressed STING pathway, optionally wherein the macrophages have reduced expression of IFN-β.

### Claim 22 (depends on 17, 19)

A transfected human macrophage according to claim 17, or a population of transfected human macrophages according to claim 19, wherein the macrophage is non-virally transfected.

### Claim 23 (depends on 16, 17, 19, 20)

A transfected human macrophage according to claims 16 or 17, or a population of transfected human macrophages according to claims 19 or 20, for use as a medicament.

### Claim 24 (depends on 23)

A transfected human macrophage or population thereof for use according to claim 23, in the treatment of a fibrotic disease, optionally a fibrotic liver disease.

### Claim 25 (depends on 23, 24)

A transfected human macrophage or a population thereof for use according to claim 23 or 24, wherein the human macrophage is autologous or allogenic to the donor.
